Overall rank by patents
#3,966
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Evalve, Inc.
USPTO PatentsView assignee record — 91 granted patents across 4 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
91
Total patents granted
4
CPC technology areas
17.4
Avg claims per patent
+255%
5-year filing velocity
The verdict
Evalve holds 91 US patents across 4 technology areas — rank #3,966 of 50,000 tracked assignees.
- #3,966
- of 50,000 US assignees by volume
- Top 36%
- by Innovation Score (40.1/100)
- 17.4
- avg claims per patent
- +255%
- filing velocity, last 5 yrs
Portfolio overview
EVALVE, INC. has been granted 91 US utility patents between 2015 and 2025, placing EVALVE, INC. at rank #3,966 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.4 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, EVALVE, INC. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 40.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 71 grants, compared with 20 in the 2015–2019 window — a +255% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. EVALVE, INC.'s 17.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark EVALVE, INC. against peers pursuing similar technology classes.
How does EVALVE compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Evalve ◀ 91
EVALVE, INC.
91 patents
What this shows EVALVE holds 91 patents — placing it at rank #3,966 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
EVALVE's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
40 Top 36% higher than 64% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 1.1% |
| 2016 | 2 | 2.2% |
| 2017 | 1 | 1.1% |
| 2018 | 3 | 3.3% |
| 2019 | 13 | 14.3% |
| 2020 | 16 | 17.6% |
| 2021 | 8 | 8.8% |
| 2022 | 8 | 8.8% |
| 2023 | 11 | 12.1% |
| 2024 | 20 | 22.0% |
| 2025 | 8 | 8.8% |
Which technologies does EVALVE, INC. patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does EVALVE, INC. hold?
EVALVE, INC. holds 91 US granted patents filed between 2015 and 2025, spanning 4 technology areas.
What is EVALVE, INC.'s Innovation Score?
EVALVE, INC. has an Innovation Score of 40.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does EVALVE, INC. focus on?
EVALVE, INC.'s top technology area is A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS) with 79 patents. The company has filed patents in 4 CPC subclasses total.
Is EVALVE, INC.'s patent filing rate increasing or decreasing?
EVALVE, INC.'s recent filing velocity is +255% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for EVALVE, INC.'s patents?
EVALVE, INC.'s patents average 17.4 claims each. This falls within the standard range, providing solid legal coverage.
How is the EVALVE, INC. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
How to use this portfolio
Evalve's 91 grants land it in the top 36% by Innovation Score — but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance — Evalve ranks #3,966 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61F — see who else leads that technology area. A61F leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
A61F technology
EVALVE, INC.'s primary CPC class — all holders and yearly trends
Top 50 patent holders
See where EVALVE, INC. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov
